Similar articles

• Serum protein binding of diphenylhydantoin in man. I. Interaction with sodium valproate.

  Lecchini S, Gatti G, De Bernardi M, Caravaggi M, Frigo GM, Calzetti S, Visintini D. Lecchini S, et al. Farmaco Prat. 1978 Feb;33(2):80-2. Farmaco Prat. 1978. PMID: 344060 No abstract available.
• Valproate may lower serum-phenytoin.

  Bardy A, Hari R, Lehtovaara R, Majuri H. Bardy A, et al. Lancet. 1977 Jun 11;1(8024):1256-7. doi: 10.1016/s0140-6736(77)92460-6. Lancet. 1977. PMID: 68349 No abstract available.
• Valproic acid in epilepsy: clinical and pharmacological effects.

  Mattson RH, Cramer JA, Williamson PD, Novelly RA. Mattson RH, et al. Ann Neurol. 1978 Jan;3(1):20-5. doi: 10.1002/ana.410030105. Ann Neurol. 1978. PMID: 350128 Clinical Trial.
• [Valproic acid in the treatment of epilepsy with special emphasis on serum level determination (author's transl)].

  Fröscher W, Schulz HU, Gugler R. Fröscher W, et al. Fortschr Neurol Psychiatr Grenzgeb. 1978 Jun;46(6):327-41. Fortschr Neurol Psychiatr Grenzgeb. 1978. PMID: 352872 Review. German.
• Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

  Pinder RM, Brogden RN, Speight TM, Avery GS. Pinder RM, et al. Drugs. 1977 Feb;13(2):81-123. doi: 10.2165/00003495-197713020-00001. Drugs. 1977. PMID: 402258 Review.